AROS Is a Significant Biomarker for Tumor Aggressiveness in Non-cirrhotic Hepatocellular Carcinoma.
10.3346/jkms.2015.30.9.1253
- Author:
Jung Hee KWON
1
;
Keun Soo AHN
;
Young Ho MOON
;
Jin Young PARK
;
Hee Jung WANG
;
Kwan Yong CHOI
;
Gundo KIM
;
Jae Won JOH
;
Kyeong Geun LEE
;
Koo Jeong KANG
Author Information
1. Cbs Bioscience Inc., Daejeon, Korea.
- Publication Type:Original Article ; Research Support, Non-U.S. Gov't
- Keywords:
Carcinoma, Hepatocellular;
Prognosis;
Biological Markers
- MeSH:
Adult;
Age Distribution;
Aged;
Biomarkers, Tumor/*metabolism;
Carcinoma, Hepatocellular/*epidemiology/*metabolism/pathology;
Disease-Free Survival;
Female;
Humans;
Liver Cirrhosis/epidemiology/metabolism/pathology;
Liver Neoplasms/*epidemiology/*metabolism/pathology;
Male;
Middle Aged;
Neoplasm Invasiveness;
Nuclear Proteins/*metabolism;
Prevalence;
Reproducibility of Results;
Republic of Korea/epidemiology;
Risk Factors;
Sensitivity and Specificity;
Sex Distribution;
Transcription Factors/*metabolism;
Young Adult
- From:Journal of Korean Medical Science
2015;30(9):1253-1259
- CountryRepublic of Korea
- Language:English
-
Abstract:
Despite a low risk of liver failure and preserved liver function, non-cirrhotic hepatocellular carcinoma (HCC) has a poor prognosis. In the current study, we evaluated an active regulator of SIRT1 (AROS) as a prognostic biomarker in non-cirrhotic HCC. mRNA levels of AROS were measured in tumor and non-tumor tissues obtained from 283 non-cirrhotic HCC patients. AROS expression was exclusively up-regulated in recurrent tissues from the non-cirrhotic HCC patients (P=0.015) and also in tumor tissues irrespective of tumor stage (P<0.001) or BCLC stage (P<0.001). High mRNA levels of AROS were statistically significantly associated with tumor stage (P<0.001), BCLC stage (P=0.007), alpha fetoprotein (AFP) level (P=0.013), microvascular invasion (P=0.001), tumor size (P=0.036), and portal vein invasion (P=0.005). Kaplan-Meir curve analysis demonstrated that HCC patients with higher AROS levels had shorter disease-free survival (DFS) in both the short-term (P<0.001) and long-term (P=0.005) compared to those with low AROS. Cox regression analysis demonstrated that AROS is a significant predictor for DFS along with large tumor size, tumor multiplicity, vascular invasion, and poor tumor differentiation, which are the known prognostic factors. In conclusion, AROS is a significant biomarker for tumor aggressiveness in non-cirrhotic hepatocellular carcinoma.
